Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Michala Short
Based on 2 articles published since 2010
(Why 2 articles?)

Between 2010 and 2020, Michala Short wrote the following 2 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Review Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic Cancer. 2020

Dell'Oro, Mikaela / Short, Michala / Wilson, Puthenparampil / Bezak, Eva. ·Cancer Research Institute and School of Health Sciences, University of South Australia, Adelaide, SA 5001, Australia. · Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, SA 5000, Australia. · School of Engineering, University of South Australia, Adelaide, SA 5001, Australia. · Department of Physics, University of Adelaide, Adelaide, SA 5005, Australia. ·Cancers (Basel) · Pubmed #31936565.

ABSTRACT: INTRODUCTION: Despite improvements in radiation therapy, chemotherapy and surgical procedures over the last 30 years, pancreatic cancer 5-year survival rate remains at 9%. Reduced stroma permeability and heterogeneous blood supply to the tumour prevent chemoradiation from making a meaningful impact on overall survival. Hypoxia-activated prodrugs are the latest strategy to reintroduce oxygenation to radioresistant cells harbouring in pancreatic cancer. This paper reviews the current status of photon and particle radiation therapy for pancreatic cancer in combination with systemic therapies and hypoxia activators. METHODS: The current effectiveness of management of pancreatic cancer was systematically evaluated from MEDLINE RESULTS: Limited published data suggest pancreatic cancer patients undergoing carbon ion therapy and proton therapy achieve a comparable median survival time (25.1 months and 25.6 months, respectively) and 1-year overall survival rate (84% and 77.8%). Inconsistencies in methodology, recording parameters and protocols have prevented the safety and technical aspects of particle therapy to be fully defined yet. CONCLUSION: There is an increasing requirement to tackle unmet clinical demands of pancreatic cancer, particularly the lack of synergistic therapies in the advancing space of radiation oncology.

2 Clinical Trial Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer. 2013

Short, Michala / Goldstein, David / Halkett, Georgia / Reece, William / Borg, Martin / Zissiadis, Yvonne / Kneebone, Andrew / Spry, Nigel. ·Discipline of Medical Radiation Sciences, University of Sydney, and Department of Medical Oncology, Prince of Wales Hospital, Sydney, New South Wales, Australia. ·Int J Radiat Oncol Biol Phys · Pubmed #22543205.

ABSTRACT: PURPOSE: To report quality of life (QOL) results for patients receiving chemoradiation therapy for pancreatic cancer. METHODS AND MATERIALS: Eligible patients (n=41 locally advanced, n=22 postsurgery) entered the B9E-AY-S168 study and received 1 cycle of induction gemcitabine (1000 mg/m2 weekly ×3 with 1-week break) followed by 3-dimensional conformal radiation therapy (RT) (54 Gy locally advanced and 45 Gy postsurgery) and concomitant continuous-infusion 5-fluorouracil (5FU) (200 mg/m2/d throughout RT). After 4 weeks, patients received an additional 3 cycles of consolidation gemcitabine chemotherapy. Patients completed the European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-PAN26 questionnaires at baseline, before RT/5FU, at end of RT/5FU, before consolidation gemcitabine, and at treatment completion. RESULTS: The patterns of change in global QOL scores differed between groups. In the locally advanced group global QOL scores were +13, +8, +3, and +1 compared with baseline before RT/5FU (P=.008), at end of RT/5FU, before consolidation gemcitabine, and at treatment completion, respectively. In the postsurgery group, global QOL scores were -3, +4, +15, and +17 compared with baseline at the same time points, with a significant improvement in global QOL before consolidation gemcitabine (P=.03). No significant declines in global QOL were reported by either cohort. CONCLUSIONS: This study demonstrates that global QOL and associated function and symptom profiles for pancreatic chemoradiation therapy differ between locally advanced and postsurgery patients, likely owing to differences in underlying disease status. For both groups, the treatment protocol was well tolerated and did not have a negative impact on patients' global QOL.